Orthopedics
Anthera Announces Update Call Regarding Vial Problems
December 9, 2010 7:32 am | by Bio-Medicine.Org | News | CommentsHAYWARD, Calif., Dec. 9, 2010 /- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it will hold a conference call to provide an update on the ongoing investigation and...
Aromatase Inhibitors Increased Risk of Heart Disease in Postmenopausal Women with Breast Cancer
December 9, 2010 5:34 am | by AACR | News | CommentsSAN ANTONIO - Postmenopausal women who take aromatase inhibitors as a treatment for breast cancer may be at an increased risk for developing cardiovascular disease, according to the results of a meta-analysis.
Obese Women with ER-positive/HER2-negative Breast Cancer Have Poorer Survival Rates
December 9, 2010 5:34 am | by AACR | News | CommentsSAN ANTONIO - Obesity was associated with worse overall and disease-free survival in women with operable breast cancer treated with adjuvant chemotherapy, but for the first time, researchers observed this finding in only a specific subset of patients – those with estrogen receptor...
Estrogen Alone is Effective for Reducing Breast Cancer Risk
December 9, 2010 5:34 am | by AACR | News | CommentsSAN ANTONIO - While endogenous estrogen (i.e., estrogen produced by ovaries and by other tissues) does have a well-known carcinogenic impact, hormone replacement therapy (HRT) utilizing estrogen alone (the exogenous estrogen) provides a protective effect in reducing breast cancer risk,...
AACR Mourns the Loss of Elizabeth Edwards
December 8, 2010 11:32 am | by AACR | News | CommentsThe American Association for Cancer Research is deeply saddened by the loss of Elizabeth Edwards. An outspoken cancer advocate and passionate supporter of access to quality health care for all, she fought her disease in the public eye and exhibited a great deal of courage by speaking...
Millennium Research Group to Release Their Latest US Clot Management Data
December 7, 2010 8:33 am | by Bio-Medicine.Org | News | CommentsTORONTO, Dec. 7, 2010 /- Millennium Research Group (MRG), the global authority on medical technology market intelligence, will soon release their latest data on the US clot management device market. MRG's US Markets for Clot Management Devices 2011 report provides important insight...
CTCs Predict Poor Outcome From Blood Stem Cell Transplantation Therapy for Metastatic Breast Cancer
December 6, 2010 7:34 am | by AACR | News | Comments• High-dose chemotherapy and autologous stem cell transplantation is effective therapy. • Therapy may release cancer stem-like cells from bone marrow. • Patients who had low circulating tumor cells did well. SAN ANTONIO - Metastatic breast cancer patients who had circulating tumor cells...
Cylene Selected to Present CK2 Inhibitor Multiple Myeloma Data at American Society of Hematology Meeting
December 6, 2010 4:34 am | by Bio-Medicine.Org | News | CommentsSAN DIEGO, Dec. 6, 2010 /PRNewswire/ -- Cylene Pharmaceuticals, Inc. has been selected to present data describing the activity of their first-in-class CK2 inhibitor at the 52nd Annual Meeting of the American Society of Hematology (ASH), to be held on December 4-7 in Orlando, FL, the...
CareFusion to Provide Pyxis® Point-of-Care Products to Veterans Affairs Hospitals Nationwide
December 6, 2010 4:34 am | by Bio-Medicine.Org | News | CommentsSAN DIEGO, Dec. 6, 2010 /- CareFusion (NYSE: CFN ), a leading, global medical device company, today announced the award of the Pyxis® point-of-care verification suite of products across 153 U.S. Department of Veteran Affairs (VA) medical centers and 17 outpatient centers. (Logo:...
FDA approves BG Medicine heart failure test
November 23, 2010 9:34 am | by Mass High Tech: The Journal of New England Technology | News | CommentsBG Medicine Inc. has received approval from the U.S. Food and Drug Administration for its cardiac test, Galectin-3, which is designed to measure galectin-3 blood levels.
Company Finds ‘Spine-Tingling’ Alternative to Surgical Device Redesign
November 12, 2010 10:59 am | by Tom Solon and Peter Fatone | Articles | CommentsThe Project: An accelerated lead was needed on a lead screw in a spinal surgical device that would enable fewer turns to generate the necessary motion without increasing the load. The Solution: A custom assembly consisting of a combination metal-screw, polymer-based nut, and bushing system was provided that fit into the original device, eliminating any need for a redesign.
Essential Pharmaceuticals Acquires Exclusive Worldwide Rights to Family of Cell Media Products from Lifeblood Medical
October 27, 2010 10:34 am | by Bio-Medicine.Org | News | CommentsNEWTOWN, Pa., Oct. 27 /- Essential Pharmaceuticals, LLC, a private company dedicated to providing specialty reagents and solutions to the life sciences market, announced today that the Company will commence sales and distribution of three distinct animal-component-free products: serum...
Over 20 New Clinical Studies Presented on Masimo Noninvasive Patient Monitoring Technologies at the American Society of Anesthesiologists Annual Meeting
October 27, 2010 5:34 am | by Bio-Medicine.Org | News | CommentsIRVINE, Calif., Oct. 27 /- Masimo (Nasdaq: MASI ) announced today that over 20 new clinical studies showcasing Masimo noninvasive patient monitoring technologies were presented last week at the American Society of Anesthesiologists (ASA) Annual Meeting in San Diego, California. The...
Cardica's Automated Anastomosis Systems Featured at Advances In Robotic And Hybrid Coronary Revascularization Meeting
October 27, 2010 5:34 am | by Bio-Medicine.Org | News | CommentsREDWOOD CITY, Calif, Oct. 27/- Cardica, Inc. (Nasdaq: CRDC ) today announced that its C-Port® Flex-A® Anastomosis System and its PAS-Port® Proximal Anastomosis System will be featured in several demonstration and wet lab presentations at the Advances in Robotic and Hybrid...
Stealthy Anexon raises $7M for heart disease tech
October 20, 2010 9:33 am | by Mass High Tech: The Journal of New England Technology | News | CommentsStealthy cardiovascular biotech Anexon Inc. reports it has raised $7 million in new venture financing, naming the prestigious Mayo Clinic as an investor.
ERT to Announce Third Quarter 2010 Results on November 4, 2010
October 20, 2010 9:33 am | by Bio-Medicine.Org | News | CommentsPHILADELPHIA, Oct. 20 /- ERT (Nasdaq: ERES ) announced today that it will release its results for the third quarter 2010 on Thursday, November 4, 2010, after the market closes. After the release, the Company will host a conference call at 5:00 PM EDT that day. For the conference call,...
Cardiogenesis Corporation to Report 2010 Third Quarter Results on November 3rd
October 20, 2010 4:32 am | by Bio-Medicine.Org | News | CommentsIRVINE, Calif., Oct. 20 /- Cardiogenesis Corporation (OTCQB: CGCP) announced that the company will release results for its third quarter ended September 30, 2010 on Wednesday, November 3, 2010. The company added that Paul J. McCormick, its Executive Chairman, and William R. Abbott,...
Opto Circuits to Acquire Cardiac Science
October 19, 2010 4:32 am | by Bio-Medicine.Org | News | CommentsBOTHELL, Wash. and BANGALORE, KARNATAKA, India, Oct. 19 /- Cardiac Science Corporation (Nasdaq: CSCX ) and Opto Circuits (India) Limited [BSE Code: 532391; NSE: OPTOCIRCUI] today announced they have entered into a definitive merger agreement under which Opto Circuits has agreed to acquire...
Sagent Pharmaceuticals Announces Launch of ANEclear Device for Rapid Clearance of Inhaled Anesthetics Following Surgery
October 18, 2010 6:33 am | by Bio-Medicine.Org | News | CommentsSCHAUMBURG, Ill., Oct. 18 /- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced the commercial launch of ANEclear ™ , an easy-to-use, disposable anesthesia recovery device at the American Society of Anesthesia (ASA) meeting in San Diego....
Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today
October 18, 2010 6:33 am | by Bio-Medicine.Org | News | CommentsTHOUSAND OAKS, Calif., Oct. 18 /- Amgen (Nasdaq: AMGN ) will review the results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy) and will discuss how these results inform the appropriate use of erythropoiesis-stimulating agents (ESAs) for chronic renal...
Fenwal Named Exclusive Provider of AccuVein's Award-Winning Vein Illumination Device for Blood and Plasma Centers
October 18, 2010 6:32 am | by Bio-Medicine.Org | News | CommentsLAKE ZURICH, Ill., Oct. 18 /- Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today it has signed a three-year, exclusive agreement with AccuVein LLC to sell, market and distribute the AccuVein AV300...
Tocotrienols Shown to be Effective in Lowering Fat Levels in Blood
October 17, 2010 7:32 pm | by Bio-Medicine.Org | News | CommentsTocotrienols Shown to be Effective in Lowering Fat Levels in Blood -- SINGAPORE, Oct. 17 /PRNewswire-Asia/ --
CryoLife Announces Release Date and Teleconference Call Details for 2010 Third Quarter Financial Results
October 14, 2010 6:32 pm | by Bio-Medicine.Org | News | CommentsATLANTA, Oct. 14 /- CryoLife, Inc. (NYSE: CRY ), an implantable biological medical device and cardiovascular tissue processing company, announced today that 2010 third quarter financial results will be released on Thursday, November 4, 2010. On that day, the Company will hold a...
FDA Issues Warnings to Marketers of Unapproved 'Chelation' Products
October 14, 2010 12:32 pm | by Bio-Medicine.Org | News | CommentsSILVER SPRING, Md., Oct. 14 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today warned eight companies that their over-the-counter (OTC) chelation products are unapproved drugs and devices and that it is a violation of federal law to make unproven claims about these...
Octapharma Accepting Applications for Research Grants Focused on Human Protein Therapies
October 14, 2010 9:32 am | by Bio-Medicine.Org | News | CommentsHOBOKEN, N.J., Oct. 14 /- Octapharma USA is accepting applications for the Octapharma 25th Anniversary Grants Program , which supports clinical or pre-clinical research focused on human protein therapies in coagulation disorders, immune therapy, intensive care and emergency medicine. The...
